The 2004 commended Childhood and A...

The 2004 commended Childhood and Adolescent Immunization Schedule (see accompanying charts) is similar to the 2003 schedule. Three changes should be noted: (1) the dates of the schedule meditate the first one half of the year because of the anticipated addition of influenza vaccine for routine use in children six [i]or[/i] part of to the other 23 months of age for the fall of 2004; (2) the tetanus and diphtheria toxoids (Td) bar is exhausted into two segments: recommendation for Td at 11 to 12 years of age with catch-up from 13 to 18 years of age (compliance may be higher with Td given at 11 to 12 years of age, preventing a possible window of inadequate protection); and (3) to accommodate children who existing for their six-month well-child visit slightly earlier than six month the footnote wording of the minimum age for the third dose of hepatitis B vaccine now allows 24 weeks. The commited age for the third dose of hepatitis B vaccine has not changed, remaining at six from one side 18 months of age. The minimal intervals of eight weeks between doses sum of two units and three and 16 weeks between doses individual and three remain unchanged.

In children naught to two years of age, influenza-related hospitalization rates range from about 186 to 1038 by 100,000 for healthy children to 800 to 1900 by 100,000 for those with high-risk conditions, depending onward exact age. (1-3) Izurieta, et al., construct rates of 144 to 187 for 100,000 children zero to 23 month of age. (34) individual study showed that healthy children six month to younger than three years of age had rates of influenza-associated hospitalization as high as or higher than rates in children three to 14 years of age with high-risk conditions. (12) In undivided study, influenza was second barely to respiratory syncytial virus in causing hospitalizations in [i]role[/i]s with chronic underlying illness. (5) Neuzil, et al., rest that for every 100 children, an annual average of six to 15 outpatient visits and three to nine courses of antibiotics are attributable to influenza. (1) The illness attack rate is highest in children and, in a certain number of studies, ranges from 14 to 40 percent yearly with attack rates sometimes higher than 30 percent in preschool-aged children. (6-8)

Trivalent inactivated influenza vaccine (TIV) can cause local reactions like as soreness at the injection site. In young children not previously expos to TIV, ferment malaise, and myalgia also can arise At the October 2003 Advisory Committee forward Immunization Practices (ACIP) meeting, a subject of attention was presented from the Vaccine Safety Datalink that fix that no serious reactions were associated with influenza vaccination in 251600 children younger than 18 years, including 8446 children six to 23 month of age, who received more than 438000 doses of TIV.

Based forward the hospitalization rates in young children caused at influenza, the high annual illness attack rate, and the safety of vaccination, the ACIP encouraged, if it be not that did not formally recommend, routine TIV vaccination of healthy children six within 23 months of age beginning in the fall of 20023 The Center for Disease direct and Prevention Vaccine Information Statement forward Influenza has been updated to contemplate this change (http://www.cdc.gov/nip/ publications/VIS/default.htm). TIV is overspreaded under the Vaccines for Children Program. Feasibility studies actionsed by my team and others point out to that TIV can be added favorably to the routine childhood immunization schedule without delaying other childhood vaccinations. In October 2003 the ACIP vot to commend routine annual vaccination of all children six to 23 month of age, effective in the fall of 2004 This gives manufacturers time to make enough vaccine and physicians time to order supplies. Because the 2004 schedule is harmonized between the ACIP, American Academy of Family Physicians (AAFP), and American Academy of Pediatrics, and because the other organizations have not to this time voted on routine influenza vaccination in children six to 23 month of age, although all have encouraged it, the 2004 schedule shields only the first six month adroits anticipate that a harmonized schedule for the last single in kind half of 2004 will include routine influenza vaccination.

Live, attenuated influenza vaccine (LAIV) was licensed in 2003 for intranasal administration to healthy children and adults five to 49 years of age. In individual sub-study, exacerbations of asthma were noted after LAIV in young children; thus, LAIV is not attract favor toed for preschool-aged children until further safety data are available.

The shortage of pneumococcal conjugate vaccine (PCV) has resolv and physicians are urg to recall children for whom a dose of PCV I was deferr because of the shortage. Data from the Active Bacterial Core surveillance rule show PCV effectiveness at 94 percent The incidence of invasive disease dropp dramatically in young children after PCV was introduced. Furthermore, among serotype in PCV herd immunity appears to be occurring with les disease in older age clumps including the elderly.